<DOC>
	<DOCNO>NCT00000681</DOCNO>
	<brief_summary>To determine safety well effective dose sargramostim ( GM-CSF ; granulocyte-macrophage colony stimulate factor ) prevent side effect cause combined use zidovudine ( AZT ) various dos cancer-fighting drug ( doxorubicin , bleomycin , vincristine ) AIDS patient Kaposi 's sarcoma ( KS ) . Patients include study KS , type cancer occur nearly 20 percent patient AIDS . AIDS patient extensive KS require treatment effective cytotoxic ( anti-cancer ) agent reduce tumor size antiretroviral agent AZT prevent ameliorate development opportunistic infection . Due significant toxic effect cytotoxic antiviral agent bone marrow new blood cell generate , combination agent expect result complication granulocytopenia ( low granulocyte count ) . Hematopoietic growth factor GM-CSF may reduce severity duration marrow suppression . This may improve survival . Clinical trial GM-CSF HIV infected individual without granulocytopenia show progenitor cell ( early blood cell ) responsive GM-CSF .</brief_summary>
	<brief_title>A Phase I Study Combination Recombinant GM-CSF , AZT , Chemotherapy ( ABV ) ( Adriamycin , Bleomycin , Vincristine ) AIDS Kaposi 's Sarcoma</brief_title>
	<detailed_description>Patients include study KS , type cancer occur nearly 20 percent patient AIDS . AIDS patient extensive KS require treatment effective cytotoxic ( anti-cancer ) agent reduce tumor size antiretroviral agent AZT prevent ameliorate development opportunistic infection . Due significant toxic effect cytotoxic antiviral agent bone marrow new blood cell generate , combination agent expect result complication granulocytopenia ( low granulocyte count ) . Hematopoietic growth factor GM-CSF may reduce severity duration marrow suppression . This may improve survival . Clinical trial GM-CSF HIV infected individual without granulocytopenia show progenitor cell ( early blood cell ) responsive GM-CSF . AMENDED 910222 Due continue concern GM-CSF toxicity see 5 mcg/kg GM-CSF 20 mg/m2 adriamycin/BV/AZT cohort , GM-CSF dose study reduce adriamycin dose escalation continue . AMENDED 900430 Dosages AZT GM-CSF change reflect ongoing result . Original design : Patients receive combination AZT , antineoplastic chemotherapy , GM-CSF group three patient . The first group receive baseline dos , treatment well tolerate , subsequent group patient receive high dos chemotherapy , dose doxorubicin increase bleomycin , vincristine , AZT dose remain fix throughout study . The dose drug remain fixed give patient . The anticancer drug give intravenously every 2 week . AZT give every 4 hour mouth . GM-CSF self-injected subcutaneously every day day 2 - day 12 treatment cycle . Patients repeat chemotherapy every 2 week , maximum seven cycle , AZT give continuously . When maximum tolerate dose ( MTD ) chemotherapy combine GM-CSF determine , next phase study begin . Again dose chemotherapy increase group patient , every-day dose GM-CSF increase . Again , chemotherapy cycle repeat every 2 week maximum seven cycle . Patients receive physician examination laboratory test every week study 4 week study . AMENDED : Dosages AZT GM-CSF change reflect ongoing result .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Sarcoma , Kaposi</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Nonsteroidal agent acetaminophen drugrelated fever . Pentamidine inhalation prophylaxis Pneumocystis carinii pneumonia ( PCP ) patient prior history T4 count &lt; 200 cells/mm3 . Antiemetics nausea , vomit . Symptomatic treatment grade 1 2 oral toxicity . Toxicity grade accord NIAID Recommendations Grading Acute Subacute Toxic Effects ( Adults ) . Patients must newly diagnose biopsyproven advanced AIDSrelated Kaposi 's sarcoma . Exclusion Criteria Concurrent Medication : Excluded : Systemic steroid &gt; 1 week 30 day . All know marrowsuppressive agent . Any investigational drug . Patients exclude study follow reason : The presence active malignancy except basal cell carcinoma skin situ uterine cancer . Alteration mental status may permit compliance protocol . Symptomatic sensory motor neuropathy . History myocardial infarction significant arrhythmia . Class III/IV functional capacity cardiac patient . Prior Medication : Excluded : Cytotoxic chemotherapy . Excluded within 1 week study entry : Therapy Kaposi 's sarcoma , include interferon , immunomodulators , antiretroviral agent . Patients may follow disease symptom : Allergy bleomycin . The presence active malignancy except basal cell carcinoma skin situ uterine cancer . Alteration mental status may permit compliance protocol . Symptomatic sensory motor neuropathy . History myocardial infarction significant arrhythmia . Class III/IV functional capacity cardiac patient . Concurrent serious infection , Pneumocystis carinii pneumonia ( PCP ) , toxoplasma brain abscess , cytomegalovirus ( CMV ) retinitis colitis , cryptococcal meningitis , symptomatic Mycobacterium avium intracellulare ( MAI ) .</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Vincristine</keyword>
	<keyword>Doxorubicin</keyword>
	<keyword>Drug Evaluation</keyword>
	<keyword>Drug Therapy , Combination</keyword>
	<keyword>Granulocyte-Macrophage Colony-Stimulating Factor</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Zidovudine</keyword>
	<keyword>Bleomycin</keyword>
</DOC>